文献速递造血干细胞移植与细胞治疗白血病

清髓性预处理后单倍体与脐血移植结局比较

Comparison of haploidentical and umbilical cord blood transplantation after myeloablative conditioning.
PubMed 文献 · Blood Adv · 2021-01-01

该研究比较了清髓性预处理后单倍体造血干细胞移植(haplo-HSCT,n=375)与脐血移植(UCB,n=333)的结局。3年生存率相似(haplo 66%,≤5/8 UCB 61%,6-8/8 UCB 58%);

要点

  • 清髓性预处理后haplo-HSCT与UCB移植的3年总生存率相当。
  • ≤5/8 UCB组3年复发率低于haplo和6-8/8 UCB组,但非复发死亡率更高。
  • haplo-HSCT采用移植后环磷酰胺(PTCy)方案,所有供者均为4/8 HLA相合。

核心结论

  • 清髓性预处理后采用PTCy的haplo-HSCT,无论HLA相合程度如何,其总生存结局与UCB移植相当。

研究设计与样本

  • 回顾性比较研究,纳入接受清髓性预处理后haplo-HSCT(n=375)或UCB移植(n=333)的血液恶性肿瘤患者。
  • haplo-HSCT供者均为4/8 HLA相合;UCB移植中6-8/8 HLA相合145例,≤5/8相合188例。

主要发现

  • 3年生存率:haplo-HSCT组66%,≤5/8 UCB组61%,6-8/8 UCB组58%。
  • 6-8/8 UCB组受者更年轻(14岁 vs 21岁和29岁),合并症评分更低(81% vs 69%和63%)。
  • UCB组更多为急性淋巴细胞白血病且处于第二次完全缓解,haplo-HSCT组更多为急性髓系白血病首次完全缓解。

临床怎么用

  • 清髓性预处理后,haplo-HSCT可作为与UCB移植相当的供者选择方案。
  • 选择≤5/8 UCB移植需权衡其较低的复发率与较高的非复发死亡率。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Haploidentical hematopoietic stem cell transplantation (haplo-HSCT) has emerged as an important treatment modality. Most reports comparing haplo-HSCT with posttransplant cyclophosphamide (PTCy) and other donor sources have focused on outcomes in older adults treated with reduced intensity conditioning. Therefore, in the current study, we evaluated outcomes in patients with hematological malignancy treated with myeloablative conditioning prior to haplo- (n = 375) or umbilical cord blood (UCB; n = 333) HSCT. All haplo recipients received a 4 of 8 HLA-matched graft, whereas recipients of UCB were matched at 6-8/8 (n = 145) or ≤5/8 (n = 188) HLA antigens. Recipients of 6-8/8 UCB transplants were younger (14 years vs 21 and 29 years) and more likely to have lower comorbidity scores compared with recipients of ≤5/8 UCB and haplo-HSCT (81% vs 69% and 63%, respectively). UCB recipients were more likely to have acute lymphoblastic leukemia and transplanted in second complete remission (CR), whereas haplo-HSCT recipients were more likely to have acute myeloid leukemia in the first CR. Other characteristics, including cytogenetic risk, were similar. Survival at 3 years was similar for the donor sources (66% haplo- and 61% after ≤5/8 and 58% after 6-8/8 UCB). Notably, relapse at 3 years was lower in recipients of ≤5/8 UCB (21%, P = .03) compared with haplo- (36%) and 6-8/8 UCB (30%). However, nonrelapse mortality was higher in ≤5/8 UCB (21%) compared with other groups (P < .0001). These data suggest that haplo-HSCT with PTCy after myeloablative conditioning provides an overall survival outcome comparable to that after UCB regardless HLA match group.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Wagner JE, Ballen KK, Zhang MJ, et al. Comparison of haploidentical and umbilical cord blood transplantation after myeloablative conditioning. Blood Adv. 2021. PMID: 34461630. doi:10.1182/bloodadvances.2021004462

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。